Accession Number : AD1031089


Title :   Transplantation of Reprogrammed Autologous Stem Cells for Chronic Pain and Drug Abuse


Descriptive Note : Technical Report,30 Sep 2011,29 Apr 2016


Corporate Author : University of Illinois at Chicago Chicago United States


Personal Author(s) : Qu,Tingyu


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1031089.pdf


Report Date : 01 Jul 2016


Pagination or Media Count : 58


Abstract : This project is a Partnering PI option with Dr. Jianguo Cheng at CCF as Initiating PI and Dr. Tingyu Qu at UIC as Partnering PI. The specific aims are to generate functional chromaffin-like cells (CLCs) from mesenchymal stem cells (MSCs) and to investigate the analgesic and anti-tolerance effects and the safety of CLCs in animal models. We have conducted the proposed experiments as outlined in SOW. Specifically,we have produced CLCs by reprogramming human MSCs (hMSCs) with the extracts of porcine adrenal chromaffin cells. We have harvested bone marrow tissues from rats and isolated, cultured, and expanded rat MSCs (rMSCs) for the targeted reprogramming by using cellular extracts of porcine adrenal chromaffin cells to produce CLCs. Spinal injection of human CLCs (hCLCs) in rats produced significant anti-nociceptive effects. No tumor formation and abnormal cell growth were found in SCID mice with hCLC transplantation, suggesting the safety of these cells and their parent cells, i.e., hMSCs, as therapeutics. Recently, we found that even nave MSCs at their early passages(passage 5) had significant analgesic and robust anti-tolerance effects in both cellular and animal models. Our research has led to 5 posterpresentations at conferences, 3 publications, one published patent, and 2 manuscripts currently in preparation.


Descriptors :   stem cells , pain management , therapeutics , drug abuse , cultured cells , TOLERANCES PHYSIOLOGY


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE